154 related articles for article (PubMed ID: 36404242)
1. Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron.
Eitel KB; Hodax JK; DiVall S; Kidd KM; Salehi P; Sequeira GM
J Adolesc Health; 2023 Feb; 72(2):307-311. PubMed ID: 36404242
[TBL] [Abstract][Full Text] [Related]
2. Association of Pubertal Blockade at Tanner 2/3 With Psychosocial Benefits in Transgender and Gender Diverse Youth at Hormone Readiness Assessment.
McGregor K; McKenna JL; Williams CR; Barrera EP; Boskey ER
J Adolesc Health; 2024 Apr; 74(4):801-807. PubMed ID: 38099903
[TBL] [Abstract][Full Text] [Related]
3. Transgender Dependent Adolescents in the U.S. Military Health Care System: Demographics, Treatments Sought, and Health Care Service Utilization.
Van Donge N; Schvey NA; Roberts TA; Klein DA
Mil Med; 2019 May; 184(5-6):e447-e454. PubMed ID: 30325452
[TBL] [Abstract][Full Text] [Related]
4. Leuprolide Acetate and QTc Interval in Gender-Diverse Youth.
Waldner RC; Doulla M; Atallah J; Rathwell S; Grimbly C
Transgend Health; 2023 Feb; 8(1):84-88. PubMed ID: 36895314
[TBL] [Abstract][Full Text] [Related]
5. Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands.
van der Loos MATC; Hannema SE; Klink DT; den Heijer M; Wiepjes CM
Lancet Child Adolesc Health; 2022 Dec; 6(12):869-875. PubMed ID: 36273487
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
[TBL] [Abstract][Full Text] [Related]
7. Eligard: leuprolide acetate in a novel sustained-release delivery system.
Sartor O
Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
[TBL] [Abstract][Full Text] [Related]
8. Eating disorder symptoms among transgender and gender diverse youth.
Kramer R; Aarnio-Peterson CM; Conard LA; Lenz KR; Matthews A
Clin Child Psychol Psychiatry; 2024 Jan; 29(1):30-44. PubMed ID: 37343277
[TBL] [Abstract][Full Text] [Related]
9. Puberty Assessment and Consideration of Gonadotropin-Releasing Hormone Agonists in Transgender and Gender-Diverse Youth.
Lee JY
Pediatr Ann; 2023 Dec; 52(12):e462-e466. PubMed ID: 38049185
[TBL] [Abstract][Full Text] [Related]
10. Transgender Youth Referred to Clinics for Gender-Affirming Medical Care in Canada.
Bauer GR; Pacaud D; Couch R; Metzger DL; Gale L; Gotovac S; Mokashi A; Feder S; Raiche J; Speechley KN; Temple Newhook J; Ghosh S; Sansfaçon AP; Susset F; Lawson ML;
Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34620727
[TBL] [Abstract][Full Text] [Related]
11. Growth in Transgender/Gender-Diverse Youth in the First Year of Treatment With Gonadotropin-Releasing Hormone Agonists.
Schulmeister C; Millington K; Kaufman M; Finlayson C; Kennedy JO; Garofalo R; Chan YM; Rosenthal SM
J Adolesc Health; 2022 Jan; 70(1):108-113. PubMed ID: 34315674
[TBL] [Abstract][Full Text] [Related]
12. Physiological and Metabolic Characteristics of a Cohort of Transgender and Gender-Diverse Youth in the United States.
Millington K; Schulmeister C; Finlayson C; Grabert R; Olson-Kennedy J; Garofalo R; Rosenthal SM; Chan YM
J Adolesc Health; 2020 Sep; 67(3):376-383. PubMed ID: 32417098
[TBL] [Abstract][Full Text] [Related]
13. Bone Health in the Transgender and Gender Diverse Youth Population.
Lee JY
Curr Osteoporos Rep; 2023 Aug; 21(4):459-471. PubMed ID: 37395890
[TBL] [Abstract][Full Text] [Related]
14. Behavioral and neurobiological effects of GnRH agonist treatment in mice-potential implications for puberty suppression in transgender individuals.
Anacker C; Sydnor E; Chen BK; LaGamma CC; McGowan JC; Mastrodonato A; Hunsberger HC; Shores R; Dixon RS; McEwen BS; Byne W; Meyer-Bahlburg HFL; Bockting W; Ehrhardt AA; Denny CA
Neuropsychopharmacology; 2021 Apr; 46(5):882-890. PubMed ID: 32919399
[TBL] [Abstract][Full Text] [Related]
15. Mental Healthcare Utilization of Transgender Youth Before and After Affirming Treatment.
Hisle-Gorman E; Schvey NA; Adirim TA; Rayne AK; Susi A; Roberts TA; Klein DA
J Sex Med; 2021 Aug; 18(8):1444-1454. PubMed ID: 34247956
[TBL] [Abstract][Full Text] [Related]
16. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
Kappy M; Stuart T; Perelman A; Clemons R
J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
[TBL] [Abstract][Full Text] [Related]
17. Gender affirming medical care of transgender youth.
Salas-Humara C; Sequeira GM; Rossi W; Dhar CP
Curr Probl Pediatr Adolesc Health Care; 2019 Sep; 49(9):100683. PubMed ID: 31735692
[TBL] [Abstract][Full Text] [Related]
18. Gender-Affirming Care of Transgender and Gender-Diverse Youth: Current Concepts.
Lee JY; Rosenthal SM
Annu Rev Med; 2023 Jan; 74():107-116. PubMed ID: 36260812
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty].
Mericq G MV; Youlton R R; Willshaw Z ME
Rev Med Chil; 2006 Jul; 134(7):821-6. PubMed ID: 17130963
[TBL] [Abstract][Full Text] [Related]
20. Prioritizing Gender-Affirming Care for Youth: The Role of Pediatric-Focused Clinicians.
Salvetti B; Gallagher M; Schapiro NA; Daley AM
J Pediatr Health Care; 2024; 38(2):253-259. PubMed ID: 38429038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
